Related Experiment Video

Updated: Jul 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

M A Chaudry1, K Sales, P Ruf

  • 1University Department of Surgery, Royal Free and University College London Medical School, Pond St, London, UK. asifchaudry@doctors.net.uk

British Journal of Cancer
|February 28, 2007
PubMed

Insights

Immunotherapy targeting EpCAM (epithelial cell adhesion molecule) shows promise for gastrointestinal cancers. Early trials with EpCAM antibodies demonstrate potential in reducing mortality and activating immune responses against tumors.

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Gastrointestinal malignancy is a leading cause of cancer mortality despite surgical and adjuvant treatments.
  • Immunotherapy offers a novel approach by leveraging the immune system to eliminate cancer cells.
  • Epithelial cell adhesion molecule (EpCAM) is differentially expressed on gastrointestinal tumors, making it a potential immunotherapy target.

Purpose of the Study:

  • To review the role of EpCAM as a target for immunotherapy in gastrointestinal malignancies.
  • To summarize the outcomes of clinical trials investigating EpCAM-based immunotherapies.
  • To explore the future potential of EpCAM-mediated immune activation for cancer treatment.

Main Methods:

  • Review of clinical trials involving various EpCAM-targeting agents, including naked antibodies, immunoconjugates, and vaccines.
  • Analysis of data from a randomized controlled trial of murine IgG2a Edrecolomab in advanced colorectal carcinoma.
  • Examination of ongoing clinical investigations of fully human and trifunctional antibodies.

Main Results:

  • Clinical trials with EpCAM-targeting agents have yielded variable success.
  • The murine IgG2a Edrecolomab showed a modest reduction in mortality and morbidity compared to 5FU and Levamisole in advanced colorectal cancer.
  • Newer antibody designs are being evaluated for minimal residual disease and ascites treatment.

Conclusions:

  • EpCAM is a viable target for immunotherapy in gastrointestinal cancers.
  • While early trials show mixed results, EpCAM-based therapies hold future promise.
  • Further development of EpCAM-mediated strategies may lead to effective immune activation against gastrointestinal tumors.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...